171596-29-5 | Tadalafil

Packsize	Purity	Availability	Price	Discounted Price
1g	95%	in stock	$25.00	$17.00
5g	95%	in stock	$44.00	$31.00
25g	95%	in stock	$97.00	$68.00
100g	95%	in stock	$289.00	$203.00
500g	95%	in stock	$906.00	$634.00

Description

• Catalog Number: AB50038
• Chemical Name: Tadalafil
• CAS Number: 171596-29-5
• Molecular Formula: C22H19N3O4
• Molecular Weight: 389.404
• MDL Number: MFCD00008493
• SMILES: O=C1N(C)CC(=O)N2[C@@H]1Cc1c([C@H]2c2ccc3c(c2)OCO3)[nH]c2c1cccc2

Computed Properties

• Complexity: 702
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 2.3

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.

  Current medical research and opinion 20150101

• Tadalafil inhibits the cAMP stimulated glucose output in the rat liver.

  Chemico-biological interactions 20140905

• Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.

  Neuropharmacology 20130101

• Effect of testosterone and frequent low-dose sildenafil/tadalafil on cavernous tissue oxidative stress of aged diabetic rats.

  Andrologia 20121201

• Quantitative analysis of sildenafil and tadalafil in various fake drugs recently distributed in Korea.

  Journal of forensic sciences 20121101

• Validation of an LC-ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samples.

  Journal of pharmaceutical and biomedical analysis 20121101

• Screening for multiple phosphodiesterase type 5 inhibitor drugs in dietary supplement materials by flow injection mass spectrometry and their quantification by liquid chromatography tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20121101

• Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks.

  Journal of pharmaceutical and biomedical analysis 20121001

• Refinements in reconstruction of penile skin loss using intra-operative prostaglandin injections, postoperative tadalafil application and negative pressure dressings.

  Journal of plastic, reconstructive & aesthetic surgery : JPRAS 20121001

• The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.

  Molecular biology reports 20121001

• Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.

  European journal of heart failure 20121001

• Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.

  Lung 20121001

• Benign prostatic hyperplasia (BPH) management in the primary care setting.

  The Canadian journal of urology 20121001

• Emerging therapies: what's new is old and what's old is new.

  The Canadian journal of urology 20121001

• Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats.

  Metabolic brain disease 20120901

• Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves.

  BJU international 20120901

• Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection?

  International journal of impotence research 20120901

• Re: Matthias Oelke, François Giuliano, Vincenzo Mirone, et al., monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25.

  European urology 20120901

• The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.

  American journal of respiratory and critical care medicine 20120901

• Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck.

  The journal of sexual medicine 20120901

• Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.

  Current heart failure reports 20120901

• Re: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Re: Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.

  The Journal of urology 20120901

• The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20120901

• Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

  Drugs & aging 20120901

• Viagra and Cialis for heart failure? Erectile dysfunction drugs may do what no others have done.

  Harvard heart letter : from Harvard Medical School 20120901

• Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.

  Journal of the American College of Cardiology 20120821

• PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.

  Cancer science 20120801

• Re: Matthias Oelke, François Giuliano, Vincenzo Mirone, Lei Xu, David Cox, Lars Viktrup. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61:917-25.

  European urology 20120801

• Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.

  The Journal of urology 20120801

• Evaluation of erectile function after laparoscopic radical prostatectomy in a single center.

  The Canadian journal of urology 20120801

• I have had atrial fibrillation for six years and was recently diagnosed with pulmonary arterial hypertension (PAH). I was taken off warfarin (Coumadin) and was put on tadalafil (Adcirca). What can you tell me about PAH and will I be on Adcirca for a long time?

  Heart advisor 20120801

• Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

  Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20120801

• Selective imaging of active pharmaceutical ingredients in powdered blends with common excipients utilizing two-photon excited ultraviolet-fluorescence and ultraviolet-second order nonlinear optical imaging of chiral crystals.

  Analytical chemistry 20120717

• Phosphodiesterase 5 inhibitors in vascular systemic disorders.

  Joint, bone, spine : revue du rhumatisme 20120701

• Analysis of counterfeit Cialis® tablets using Raman microscopy and multivariate curve resolution.

  Journal of pharmaceutical and biomedical analysis 20120701

• The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism.

  Asian journal of andrology 20120701

• Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.

  Expert opinion on pharmacotherapy 20120701

• Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.

  The journal of spinal cord medicine 20120701

• Dysfunction of the endothelial-platelet pathway in patients with erectile dysfunction before and after daily treatment with tadalafil.

  Andrologia 20120601

• Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats.

  Human & experimental toxicology 20120601

• Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20120601

• Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study.

  International urology and nephrology 20120601

• Initial experience with tadalafil in pediatric pulmonary arterial hypertension.

  Pediatric cardiology 20120601

• Intra-abdominal pressure, LUTS, and tadalafil. Re: Andersson K-E, et al. tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol urodyn 2011;30:292-301.

  Neurourology and urodynamics 20120601

• Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.

  The Lancet. Oncology 20120601

• Anterior ischemic optic neuropathy associated with udenafil.

  Korean journal of ophthalmology : KJO 20120601

• Tadalafil for prevention of renal dysfunction secondary to renal ischemia.

  The Canadian journal of urology 20120601

• Identification of phototransformation products of sildenafil (Viagra) and its N-demethylated human metabolite under simulated sunlight.

  Journal of mass spectrometry : JMS 20120601

• Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

  Korean journal of urology 20120601

• Treatment of pulmonary arterial hypertension in connective tissue disease.

  Drugs 20120528

• Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20120515

• Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats.

  Andrologia 20120501

• Recurrent ischemic stroke associated with sildenafil and tadalafil use in a young adult.

  Clinical neurology and neurosurgery 20120501

• Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.

  European urology 20120501

• Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

  European urology 20120501

• Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13.

  European urology 20120501

• Monotherapy with α-blocker or phosphodiesterase 5 inhibitor for lower urinary tract symptoms?

  European urology 20120501

• A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

  European urology 20120501

• A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.

  The journal of sexual medicine 20120501

• [Effects of tadalafil on erectile dysfunction: on-demand versus once-daily dosing].

  Zhonghua nan ke xue = National journal of andrology 20120501

• [Tadalafil improves total testosterone, IIEF score and SEP in old and middle-aged males with late-onset hypogonadism].

  Zhonghua nan ke xue = National journal of andrology 20120501

• The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise.

  American journal of physiology. Endocrinology and metabolism 20120415

• Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil.

  BJU international 20120401

• Nitric oxide synthases: regulation and function.

  European heart journal 20120401

• Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.

  International journal of andrology 20120401

• Immunohistochemical and functional characterization of nitric oxide signaling pathway in isolated aorta from Crotalus durissus terrificus.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20120401

• Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.

  The journal of sexual medicine 20120401

• Nonoperative management of scleroderma of the hand with tadalafil and subatmospheric pressure wound therapy: case report.

  The Journal of hand surgery 20120401

• Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.

  Urology 20120401

• Simultaneous determination of diastereoisomeric and enantiomeric impurities in (1R, 3R)-1-(1,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester a key intermediate of tadalafil by chiral high-performance liquid chromatography.

  Chirality 20120401

• Tadalafil for the treatment of pulmonary arterial hypertension.

  Expert opinion on pharmacotherapy 20120401

• Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist?

  BJU international 20120401

• Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.

  Bioorganic & medicinal chemistry letters 20120401

• Stability of an extemporaneously prepared tadalafil suspension.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120401

• How to interpret a functional or motility test - sphincter of oddi manometry.

  Journal of neurogastroenterology and motility 20120401

• Re: Tadalafil Versus Solifenacin for Persistent Storage Symptoms After Prostate Surgery in Patients With Erectile Dysfunction: A Prospective Randomized Study.

  The Journal of urology 20120401

• Erectile dysfunction drug approved to treat BPH symptoms.

  Mayo Clinic health letter (English ed.) 20120401

• A new methodology for detection of counterfeit Viagra® and Cialis® tablets by image processing and statistical analysis.

  Forensic science international 20120310

• Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.

  Circulation research 20120302

• Oral tadalafil reduces intra-abdominal adhesion reformation in rats.

  Human reproduction (Oxford, England) 20120301

• Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts.

  Basic research in cardiology 20120301

• Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.

  Hypertension (Dallas, Tex. : 1979) 20120301

• Re: efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

  The Journal of urology 20120301

• Re: combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.

  The Journal of urology 20120301

• Liraglutide-associated acute pancreatitis.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120301

• Enhanced recovery from respiratory infection following treatment with a PDE-5 inhibitor: a single case study.

  Primary care respiratory journal : journal of the General Practice Airways Group 20120301

• Benign prostatic hyperplasia: from bench to clinic.

  Korean journal of urology 20120301

• Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study.

  Korean journal of urology 20120301

• [Sexual function inspection room for special penile insertion disorder].

  Zhonghua nan ke xue = National journal of andrology 20120301

• Drug-to-genome-to-drug, step 2: reversing selectivity in a series of antiplasmodial compounds.

  Journal of medicinal chemistry 20120209

• Isolation and structural characterization of two tadalafil analogs found in dietary supplements.

  Journal of pharmaceutical and biomedical analysis 20120205

• [Serous central chorioretinopathy and tadalafil: a case report].

  Journal francais d'ophtalmologie 20120201

• Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.

  The Urologic clinics of North America 20120201

• Counterfeiting of drugs in Brazil.

  Revista de saude publica 20120201

• Type B aortic dissection after the use of tadalafil.

  The Annals of thoracic surgery 20120201

• Prevalence of erectile dysfunction in chronic renal disease patients on conservative treatment.

  Clinics (Sao Paulo, Brazil) 20120201

• Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry.

  Journal of pharmaceutical and biomedical analysis 20120125

• Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.

  European journal of pharmacology 20120115

• Capsule shells adulterated with tadalafil.

  Forensic science international 20120110

• Circulating endothelial progenitor cells and endothelial microparticles in patients with arterial erectile dysfunction and metabolic syndrome.

  Journal of andrology 20120101

• Endothelial antioxidant compound prolonged the endothelial antiapoptotic effects registered after tadalafil treatment in patients with arterial erectile dysfunction.

  Journal of andrology 20120101

• Arterial erectile dysfunction: reliability of penile Doppler evaluation integrated with serum concentrations of late endothelial progenitor cells and endothelial microparticles.

  Journal of andrology 20120101

• Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.

  Journal of andrology 20120101

• Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

  The journal of sexual medicine 20120101

• Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile.

  The journal of sexual medicine 20120101

• 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.

  The journal of sexual medicine 20120101

• Central serous chorioretinopathy following oral tadalafil.

  Eye (London, England) 20120101

• Tadalafil and pulmonary arterial hypertension.

  Clinical therapeutics 20120101

• Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?

  Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20120101

• How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.

  The journal of sexual medicine 20120101

• Inhaled treprostinil: a therapeutic review.

  Drug design, development and therapy 20120101

• [Alternate-day oral tadalafil for erectile dysfunction with no successful intercourse at the baseline].

  Zhonghua nan ke xue = National journal of andrology 20120101

• Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation.

  Core evidence 20120101

• Optical coherence tomography in tadalafil-associated retinal toxicity.

  European journal of ophthalmology 20120101

• Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study.

  Surgical neurology international 20120101

• Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.

  BMJ (Clinical research ed.) 20120101

• Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication.

  International braz j urol : official journal of the Brazilian Society of Urology 20120101

• Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa.

  Journal of translational medicine 20120101

• Bilateral simultaneous nonarteritic anterior ischemic optic neuropathy after ingestion of sildenafil for erectile dysfunction.

  Case reports in medicine 20120101

• Analysis of the therapeutic effect of tadalafil on male ED after transurethral resection of prostate.

  International journal of impotence research 20120101

• Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension.

  PloS one 20120101

• Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study.

  BMJ open 20120101

• cGMP-phosphodiesterase inhibition enhances photic responses and synchronization of the biological circadian clock in rodents.

  PloS one 20120101

• Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.

  TheScientificWorldJournal 20120101

• Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment.

  International journal of hypertension 20120101

• The end-organ impairment in liver cirrhosis: appointments for critical care.

  Critical care research and practice 20120101

• [Erectile dysfunction: conservative treatment and new approaches].

  Revue medicale de Bruxelles 20120101

• Acclimatizing with acetazolamide.

  Journal of travel medicine 20120101

• Tadalafil and acetazolamide versus acetazolamide for the prevention of severe high-altitude illness.

  Journal of travel medicine 20120101

• Quantitation of transdermal tadalafil in human skin by reversed-phase high-performance liquid chromatography.

  Journal of AOAC International 20120101

• Avanafil for treatment of erectile dysfunction: review of its potential.

  Vascular health and risk management 20120101

• Effects of systemic tadalafil on skin flap survival in rats.

  Eplasty 20120101

• Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice.

  PloS one 20120101

• Effect of novel synthetic evodiamine analogue on sexual behavior in male rats.

  Journal of chemical biology 20120101

• Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20120101

• [Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].

  Revue medicale suisse 20111207

• Identification of novel sildenafil-analogues in an adulterated herbal food supplement.

  Journal of pharmaceutical and biomedical analysis 20111205

• PDE5 inhibitors: targeting erectile dysfunction in diabetics.

  Current opinion in pharmacology 20111201

• Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.

  The journal of sexual medicine 20111201

• Pulmonary arterial hypertension: an update.

  Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201

• Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era.

  Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201

• Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.

  The Annals of pharmacotherapy 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Analysis of prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors from the urology department and other departments.

  International neurourology journal 20111201

• cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

  Current neuropharmacology 20111201

• Therapy: two birds, one stone: tadalafil is an effective treatment for men with both BPH-LUTS and ED.

  Nature reviews. Urology 20111115

• Tadalafil (Cialis) for signs and symptoms of benign prostatic hyperplasia.

  The Medical letter on drugs and therapeutics 20111114

• Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.

  British journal of cancer 20111108

• Development and validation of a GC/MS method for the determination of tadalafil in whole blood.

  Journal of pharmaceutical and biomedical analysis 20111101

• Determination of tadalafil and N-desmethylsibutramine in health and dietary supplements using ultra-performance liquid chromatography (UPLC) coupled with quadrupole-time-of-flight mass spectrometry (Q-TOF MS).

  Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 20111101

• Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale.

  European urology 20111101

• Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

  European urology 20111101

• Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.

  Clinical therapeutics 20111101

• Tadalafil: visual and auditory disorders. Inform patients of these risks.

  Prescrire international 20111101

• Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism.

  Korean journal of urology 20111101

• Sexual dysfunction: MCID provides new perspective on erectile function research.

  Nature reviews. Urology 20111018

• Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.

  Cellular signalling 20111001

• Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.

  The journal of sexual medicine 20111001

• New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome: effects of tadalafil administration.

  International angiology : a journal of the International Union of Angiology 20111001

• Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.

  The journal of sexual medicine 20111001

• Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).

  Expert opinion on therapeutic patents 20111001

• [Tadalafil for ED after transurethral resection of the prostate: a report of 113 cases].

  Zhonghua nan ke xue = National journal of andrology 20111001

• Impurity fingerprints for the identification of counterfeit medicines--a feasibility study.

  Analytica chimica acta 20110909

• Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release.

  British journal of pharmacology 20110901

• Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.

  European urology 20110901

• A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.

  The journal of sexual medicine 20110901

• Preparation of imprinted polymers at surface of magnetic nanoparticles for the selective extraction of tadalafil from medicines.

  ACS applied materials & interfaces 20110901

• [Psychosomatic treatment: a key to the improvement of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20110901

• Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

  British journal of clinical pharmacology 20110801

• Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.

  Clinical therapeutics 20110801

• The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation.

  The journal of sexual medicine 20110801

• The effects of tadalafil on renal ischemia reperfusion injury: an experimental study.

  Bosnian journal of basic medical sciences 20110801

• A case of laparoscopic radical prostatectomy for a prostatic stromal tumor of uncertain malignant potential.

  Korean journal of urology 20110801

• Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.

  Journal of clinical pharmacology 20110701

• Prevalence and medical management of erectile dysfunction in Asia.

  Asian journal of andrology 20110701

• Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound.

  The Journal of urology 20110701

• Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study.

  International journal of urology : official journal of the Japanese Urological Association 20110701

• Subarachnoid hemorrhage associated with tadalafil.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110701

• Identify drug repurposing candidates by mining the protein data bank.

  Briefings in bioinformatics 20110701

• Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.

  American journal of respiratory and critical care medicine 20110615

• Recreational use of erectile dysfunction medications in undergraduate men in the United States: characteristics and associated risk factors.

  Archives of sexual behavior 20110601

• Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

  BJU international 20110601

• Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20110601

• Role of a novel tetrodotoxin-resistant sodium channel in the nitrergic relaxation of corpus cavernosum from the South American rattlesnake Crotalus durissus terrificus.

  The journal of sexual medicine 20110601

• Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction.

  Journal of Zhejiang University. Science. B 20110601

• Phosphodiesterase type 5 inhibitor abuse: a critical review.

  Current drug abuse reviews 20110601

• Tadalafil for the treatment of pulmonary arterial hypertension.

  Expert review of respiratory medicine 20110601

• Effect on sexual function of a vacuum erection device post-prostatectomy.

  The Canadian journal of urology 20110601

• [Efficacy and safety of long-term small-dose tadalafil in the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20110601

• [ED patients and their female partners prefer tadalafil].

  Zhonghua nan ke xue = National journal of andrology 20110601

• Protective Effect of Coriolus versicolor Cultivated in Citrus Extract Against Nitric Oxide-Induced Apoptosis in Human Neuroblastoma SK-N-MC Cells.

  Experimental neurobiology 20110601

• Retinitis pigmentosa: genes and disease mechanisms.

  Current genomics 20110601

• Drug to genome to drug: discovery of new antiplasmodial compounds.

  Journal of medicinal chemistry 20110512

• New perspectives for the treatment of pulmonary hypertension.

  British journal of pharmacology 20110501

• Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors.

  Urology 20110501

• The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes.

  The journal of sexual medicine 20110501

• Tadalafil inclusion in microporous silica as effective dissolution enhancer: optimization of loading procedure and molecular state characterization.

  Journal of pharmaceutical sciences 20110501

• Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis.

  The journal of sexual medicine 20110401

• Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.

  BJU international 20110401

• A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method.

  Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 20110401

• The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.

  BJU international 20110401

• Interaction involving tadalafil and CYP3A4 inhibition by ritonavir.

  Scandinavian journal of infectious diseases 20110301

• Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.

  The journal of sexual medicine 20110301

• Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro.

  The journal of sexual medicine 20110301

• Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

  Neurourology and urodynamics 20110301

• Complementary medicine and erectile dysfunction: will you accept the charges?

  International journal of clinical practice 20110301

• Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.

  Archiv der Pharmazie 20110301

• The management of erectile dysfunction: innovations and future perspectives.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20110301

• Separation and structural elucidation of a novel analogue of vardenafil included as an adulterant in a dietary supplement by liquid chromatography-electrospray ionization mass spectrometry, infrared spectroscopy and nuclear magnetic resonance spectroscopy.

  Journal of pharmaceutical and biomedical analysis 20110220

• Brachial artery flow mediated assessment: a tool to predict the response to chronic PDE5 inhibition with tadalafil in patients with erectile dysfunction.

  International journal of cardiology 20110203

• Effects of sildenafil and tadalafil on ischemia/reperfusion injury in fetal rat brain.

  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 20110201

• The impact of oral ED medication on female partners' relationship satisfaction.

  The journal of sexual medicine 20110201

• Importation of prescription medicines into New Zealand: a snapshot of intercepted products.

  International journal of clinical pharmacy 20110201

• Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.

  Drugs of today (Barcelona, Spain : 1998) 20110201

• [Cardiovascular complications of phosphodiesterase-5 inhibitors].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20110201

• Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.

  Journal of medicinal chemistry 20110127

• The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups.

  Neuroscience letters 20110113

• The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study.

  BJU international 20110101

• Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice.

  The European respiratory journal 20110101

• Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).

  The journal of sexual medicine 20110101

• Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds.

  Handbook of experimental pharmacology 20110101

• Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial.

  The Journal of urology 20110101

• The effect of phosphodiesterase inhibitor tadalafil on vasospasm following subarachnoid hemorrhage in an experimental rabbit model.

  Acta neurochirurgica. Supplement 20110101

• The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats.

  Urologia internationalis 20110101

• Patients' preference in the treatment of erectile dysfunction: a critical review of the literature.

  International journal of impotence research 20110101

• Leber's hereditary optic neuropathy precipitated by tadalafil use for erectile dysfunction.

  Seminars in ophthalmology 20110101

• Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.

  Handbook of experimental pharmacology 20110101

• Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study.

  The Kaohsiung journal of medical sciences 20110101

• A high-performance liquid chromatography:chemiluminescence method for potential determination of vardenafil in dietary supplement.

  Journal of automated methods & management in chemistry 20110101

• [Benefits of tadalafil to ED patients].

  Zhonghua nan ke xue = National journal of andrology 20110101

• Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies.

  Anemia 20110101

• The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

  PloS one 20110101

• Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability.

  Patient preference and adherence 20110101

• Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models.

  PloS one 20110101

• [Pulmonary arterial hypertension: changing approaches to management].

  Kardiologiia 20110101

• Recent trends in pulmonary arterial hypertension.

  Lung India : official organ of Indian Chest Society 20110101

• Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation.

  International journal of impotence research 20110101

• Tadalafil alters energy metabolism in C2C12 skeletal muscle cells.

  Acta biochimica Polonica 20110101

• Therapeutic strategies in pulmonary hypertension.

  Frontiers in pharmacology 20110101

• Erectile dysfunction.

  BMJ clinical evidence 20110101

• Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.

  Clinical interventions in aging 20110101

• Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy.

  International braz j urol : official journal of the Brazilian Society of Urology 20110101

• Evaluation of liver transplant candidates: A pulmonary perspective.

  Annals of thoracic medicine 20110101

• Primary Raynaud's phenomenon in an infant: a case report and review of literature.

  Pediatric rheumatology online journal 20110101

• Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.

  Congenital heart disease 20110101

• Bladder, bowel, and sexual dysfunction in Parkinson's disease.

  Parkinson's disease 20110101

• [Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?].

  Kardiologia polska 20110101

• Diagnosis and management of pulmonary arterial hypertension.

  Pulmonary medicine 20110101

• Anaesthesia Management of Caesarean Section in Two Patients with Eisenmenger's Syndrome.

  Anesthesiology research and practice 20110101

• Quality of online pharmacies and websites selling prescription drugs: a systematic review.

  Journal of medical Internet research 20110101

• Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.

  International heart journal 20110101

• Differential effects of organic nitrates on arterial diameter among healthy Japanese participants with different mitochondrial aldehyde dehydrogenase 2 genotypes: randomised crossover trial.

  BMJ open 20110101

• Overview of current therapeutic approaches for pulmonary hypertension.

  Pulmonary circulation 20110101

• Enhanced transdermal delivery of evodiamine and rutaecarpine using microemulsion.

  International journal of nanomedicine 20110101

• Future prospects in the treatment of erectile dysfunction: focus on avanafil.

  Drug design, development and therapy 20110101

• Vascular involvement in systemic sclerosis (scleroderma).

  Journal of inflammation research 20110101

• Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.

  International journal of rheumatology 20110101

• PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials.

  International journal of rheumatology 20110101

• Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

  Experimental and clinical cardiology 20110101

• Surgical treatment of pulmonary hypertension: Lung transplantation.

  Pulmonary circulation 20110101

• Testosterone, endothelial health, and erectile function.

  ISRN endocrinology 20110101

• Tadalafil.

  Profiles of drug substances, excipients, and related methodology 20110101

• Systemic sclerosis 2011.

  International journal of rheumatology 20110101

• In sight into tadalafil - block copolymer binary solid dispersion: Mechanistic investigation of dissolution enhancement.

  International journal of pharmaceutics 20101215

• Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.

  Rheumatology (Oxford, England) 20101201

• Key features for designing phosphodiesterase-5 inhibitors.

  Journal of biomolecular structure & dynamics 20101201

• Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.

  European respiratory review : an official journal of the European Respiratory Society 20101201

• Vardenafil Enhances Oxytocin Expression in the Paraventricular Nucleus without Sexual Stimulation.

  International neurourology journal 20101201

• Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction.

  Clinics (Sao Paulo, Brazil) 20101201

• [Efficacy of low-dose tadalafil on ED assessed by Self-Esteem and Relationship Questionnaire].

  Zhonghua nan ke xue = National journal of andrology 20101201

• Word of wisdom. Re: effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

  European urology 20101201

• Spider-venom peptides as therapeutics.

  Toxins 20101201

• Identification of amino-tadalafil and rimonabant in electronic cigarette products using high pressure liquid chromatography with diode array and tandem mass spectrometric detection.

  Journal of chromatography. A 20101126

• Comparison and combination of spectroscopic techniques for the detection of counterfeit medicines.

  Journal of pharmaceutical and biomedical analysis 20101102

• Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.

  American journal of physiology. Heart and circulatory physiology 20101101

• Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.

  Expert opinion on investigational drugs 20101101

• Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary.

  Journal of pediatric surgery 20101101

• A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20101101

• An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.

  Nature reviews. Urology 20101101

• [Daily medication of low-dose tadalafil improves endothelial function and erectile hardness of ED patients].

  Zhonghua nan ke xue = National journal of andrology 20101101

• The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.

  Current cardiology reviews 20101101

• Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.

  International journal of cardiology 20101029

• [Dietary supplements on the domestic market adulterated with sildenafil and tadalafil].

  Orvosi hetilap 20101024

• Haemodynamic and renal effects of tadalafil in patients with cirrhosis.

  World journal of gastroenterology 20101021

• A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015

• Counterfeit drugs detection by measurement of tablets and secondary packaging colour.

  Journal of pharmaceutical and biomedical analysis 20101010

• Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes.

  Diabetologia 20101001

• Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction.

  The journal of sexual medicine 20101001

• Anabolic, doping, and lifestyle drugs, and selected metabolites in wastewater--detection, quantification, and behaviour monitored by high-resolution MS and MS(n) before and after sewage treatment.

  Analytical and bioanalytical chemistry 20101001

• Phosphodiesterase-5 inhibitor tadalafil acts on endothelial progenitor cells by CXCR4 signalling.

  Current drug delivery 20101001

• Oral therapy for erectile dysfunction.

  Archivos espanoles de urologia 20101001

• The future of erectile dysfunction (ED).

  Archivos espanoles de urologia 20101001

• [Nocturnal penile tumescence and the effect of tadalafil on erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20101001

• Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses.

  European heart journal 20100901

• Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

  The Journal of pharmacology and experimental therapeutics 20100901

• Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.

  Behavioural pharmacology 20100901

• cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

  Pharmacological reviews 20100901

• [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20100901

• Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study.

  Korean journal of urology 20100901

• The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury.

  International journal of impotence research 20100901

• Stuttering priapism: case report and bibliographic review.

  Archivos espanoles de urologia 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• [Standard doses of tadalafil for different ED patients].

  Zhonghua nan ke xue = National journal of andrology 20100901

• Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.

  Annals of the rheumatic diseases 20100801

• Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study.

  Angiology 20100801

• Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.

  Endocrinology 20100801

• Investigation on the phototransformation of tadalafil in aqueous media. 6-Epimerization vs. solvent trapping reaction.

  Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 20100801

• Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4.

  Urology 20100801

• Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.

  The journal of sexual medicine 20100801

• cGMP is required for seed germination in Arabidopsis thaliana.

  Journal of plant physiology 20100715

• Screening of Indian aphrodisiac ayurvedic/herbal healthcare products for adulteration with sildenafil, tadalafil and/or vardenafil using LC/PDA and extracted ion LC-MS/TOF.

  Journal of pharmaceutical and biomedical analysis 20100708

• Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.

  Journal of human hypertension 20100701

• Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

  Current urology reports 20100701

• Simultaneous determination of yohimbine, sildenafil, vardenafil and tadalafil in dietary supplements using high-performance liquid chromatography-tandem mass spectrometry.

  Journal of separation science 20100701

• Severe hypoglycaemia associated with ingesting counterfeit medication.

  The Medical journal of Australia 20100621

• A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine.

  Rapid communications in mass spectrometry : RCM 20100615

• Sildenafil promotes adipogenesis through a PKG pathway.

  Biochemical and biophysical research communications 20100611

• Effects of sildenafil and tadalafil on intraocular pressure in sheep: implications for aqueous humor dynamics.

  Investigative ophthalmology & visual science 20100601

• Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction.

  Neurourology and urodynamics 20100601

• Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

  Urology 20100601

• Impact of tadalafil once daily in men with erectile dysfunction--including a report of the partners' evaluation.

  Urology 20100601

• Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis.

  The journal of sexual medicine 20100601

• Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.

  Current medical research and opinion 20100601

• Expression of cyclic AMP-dependent protein kinase isoforms in human cavernous arteries: functional significance and relation to phosphodiesterase type 4.

  The journal of sexual medicine 20100601

• The effect of tadalafil on anastomotic healing in ischemic small intestine in rats.

  Surgery today 20100601

• Editorial comment.

  Urology 20100601

• Editorial comment.

  Urology 20100601

• Editorial comment.

  Urology 20100601

• A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.

  BJU international 20100601

• Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.

  Wilderness & environmental medicine 20100601

• [Benefits of tadalafil in sexual activity-related time concerns].

  Zhonghua nan ke xue = National journal of andrology 20100601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100601

• Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.

  European urology 20100501

• Phosphodiesterase type 5 inhibitor use and hearing impairment.

  Archives of otolaryngology--head & neck surgery 20100501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100501

• Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro.

  European urology 20100401

• Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.

  Journal of biomolecular structure & dynamics 20100401

• Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.

  European journal of medicinal chemistry 20100401

• Effects of sildenafil on autonomic nervous function during sleep in obstructive sleep apnea.

  Clinics (Sao Paulo, Brazil) 20100401

• [Effectiveness and treatment satisfaction in patients with erectile dysfunction in Spain: EDOS study].

  Actas urologicas espanolas 20100401

• Failure of PDE5 inhibitor use: a case of nonresponder? (CME).

  The journal of sexual medicine 20100401

• Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects.

  International neurourology journal 20100401

• Long term combination treatment for severe idiopathic pulmonary arterial hypertension.

  World journal of cardiology 20100326

• Systemic and metabolic effects of PDE5-inhibitor drugs.

  World journal of diabetes 20100315

• Erectile dysfunction.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20100309

• Tadalafil: in pulmonary arterial hypertension.

  Drugs 20100305

• Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha.

  European urology 20100301

• A new approach to the treatment of cerebral vasospasm: the angiographic effects of tadalafil on experimental vasospasm.

  Acta neurochirurgica 20100301

• Protective effects of tadalafil on experimental spinal cord injury in rats.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20100301

• Chuanxiongzine relaxes isolated corpus cavernosum strips and raises intracavernous pressure in rabbits.

  International journal of impotence research 20100301

• Phosphodiesterase type V inhibitors: Occurrence and fate in wastewater and sewage sludge.

  Water research 20100301

• Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.

  Urology 20100301

• Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.

  International journal of clinical practice 20100301

• Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.

  The Journal of urology 20100301

• Prospective drug safety monitoring using the UK primary-care General Practice Research Database: theoretical framework, feasibility analysis and extrapolation to future scenarios.

  Drug safety 20100301

• [Therapy for male patients with sexual dysfunction].

  Therapeutische Umschau. Revue therapeutique 20100301

• Identification of counterfeit medicines for erectile dysfunction from an illegal supply chain.

  Arhiv za higijenu rada i toksikologiju 20100301

• [Pulmonary circulation: contributions of the year 2009].

  Archivos de bronconeumologia 20100301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100301

• Assessment of erectile and ejaculatory function after penile prosthesis implantation.

  Korean journal of urology 20100301

• [Therapy of erectile dysfunction].

  Orvosi hetilap 20100227

• Phosphodiesterase inhibitors for pulmonary hypertension.

  The New England journal of medicine 20100211

• The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis and the optical purity of tadalafil stereoisomers.

  Journal of pharmaceutical and biomedical analysis 20100205

• Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.

  BJU international 20100201

• Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency.

  BJU international 20100201

• Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?

  The journal of sexual medicine 20100201

• Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study.

  Retina (Philadelphia, Pa.) 20100201

• The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).

  Southern medical journal 20100201

• Management of erectile dysfunction.

  American family physician 20100201

• [Guidelines for the diagnosis and treatment of pulmonary hypertension].

  Revue des maladies respiratoires 20100201

• Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.

  Drug testing and analysis 20100201

• Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success.

  International journal of impotence research 20100101

• Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction.

  The journal of sexual medicine 20100101

• Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors.

  The journal of sexual medicine 20100101

• Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.

  Current opinion in urology 20100101

• Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

  International journal of clinical practice 20100101

• Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).

  Bioorganic & medicinal chemistry letters 20100101

• Tadalafil for the treatment of pulmonary arterial hypertension.

  Expert opinion on pharmacotherapy 20100101

• Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.

  International journal of impotence research 20100101

• Randomized, placebo-controlled, double-blind, parallel design trial of the efficacy and safety of Zestra in women with mixed desire/interest/arousal/orgasm disorders.

  Journal of sex & marital therapy 20100101

• Pharmacotherapy for erectile dysfunction.

  The journal of sexual medicine 20100101

• Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.

  Respiratory research 20100101

• Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

  BMC cardiovascular disorders 20100101

• [Cholestatic acute hepatitis induced by tadalafil (Cialis)].

  Gastroenterologie clinique et biologique 20100101

• Development of acute lympboblastic leukemia in a patient with increased hematogones after toxic bone marrow damage.

  International journal of clinical and experimental pathology 20100101

• Evidence based guidelines for complex regional pain syndrome type 1.

  BMC neurology 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

  Annals of general psychiatry 20100101

• Pharmacotherapeutic management of pulmonary arterial hypertension.

  Cardiology in review 20100101

• Recent achievements in the management of Raynaud's phenomenon.

  Vascular health and risk management 20100101

• Prevention and treatment of high-altitude pulmonary edema.

  Progress in cardiovascular diseases 20100101

• Advances in the treatment of Raynaud's phenomenon.

  Vascular health and risk management 20100101

• The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

  Vascular health and risk management 20100101

• Determination of tadalafil in pure powder and tablet dosage form by high-performance liquid chromatography.

  Journal of AOAC International 20100101

• Nitric oxide and pulmonary hypertension.

  Korean journal of anesthesiology 20100101

• Erectile dysfunction in aging male.

  Acta bio-medica : Atenei Parmensis 20100101

• Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

  Drug design, development and therapy 20100101

• [Are there counterfeit medicines in Croatia?].

  Lijecnicki vjesnik 20100101

• Modified intention to treat reporting in randomised controlled trials: systematic review.

  BMJ (Clinical research ed.) 20100101

• Testosterone and chronic sildenafil/tadalafil anti-apoptotic role in aged diabetic rats.

  International journal of impotence research 20100101

• Potentially fatal new trend in performance enhancement: a cautionary note on nitrite.

  Journal of the International Society of Sports Nutrition 20100101

• Addressing and managing erectile dysfunction after prostatectomy for prostate cancer.

  Urologic nursing 20100101

• Tadalafil-induced transient global amnesia.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• High-altitude medicine.

  Indian journal of occupational and environmental medicine 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

  Drug design, development and therapy 20100101

• Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

  Vascular health and risk management 20100101

• Digital ischemia in scleroderma spectrum of diseases.

  International journal of rheumatology 20100101

• Recent advances in management of bladder overactivity.

  F1000 medicine reports 20100101

• [Sexual function rehabilitation of men with pituitary tumors].

  Urologiia (Moscow, Russia : 1999) 20100101

• Vascular alterations and sexual function in systemic sclerosis.

  International journal of rheumatology 20100101

• Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects.

  International journal of rheumatology 20100101

• Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

  Health and quality of life outcomes 20100101

• Silodosin in the treatment of benign prostatic hyperplasia.

  Drug design, development and therapy 20100101

• New approaches in the management of multiple sclerosis.

  Drug design, development and therapy 20100101

• Improvement of urodynamic indices by single dose oral tadalafil in men with supra sacral spinal cord injury.

  Urology journal 20100101

• Inhaled treprostinil and pulmonary arterial hypertension.

  Vascular health and risk management 20100101

• Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation.

  Oxidative medicine and cellular longevity 20100101

• [Counterfeit phosphodiesterase type 5 inhibitors--growing safety risks for public health].

  Roczniki Panstwowego Zakladu Higieny 20100101

• Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers.

  Drug, healthcare and patient safety 20100101

• Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.

  Drug, healthcare and patient safety 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model.

  European journal of pharmacology 20091210

• No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

  Journal of pharmaceutical sciences 20091201

• Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.

  Cellular signalling 20091201

• Effects of 12-month tadalafil therapy for erectile dysfunction on couple relationships: results from the DETECT study.

  The journal of sexual medicine 20091201

• Sexual risk behaviors among men who have sex with men using erectile dysfunction medications.

  AIDS patient care and STDs 20091201

• Physicochemical characterization of solid dispersion systems of tadalafil with poloxamer 407.

  Acta pharmaceutica (Zagreb, Croatia) 20091201

• Vardenafil increases cell proliferation in the dentate gyrus through enhancement of serotonin expression in the rat dorsal raphe.

  Journal of Korean medical science 20091201

• Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column.

  Journal of chromatography. A 20091120

• Diagnosis and treatment of erectile dysfunction--a practical update.

  Journal of medicine and life 20091115

• [Therapy of erectile dysfunction can help man and woman. Improving the sexual quality of life of couples].

  MMW Fortschritte der Medizin 20091105

• [Interview with Dr. Heinz-Jürgen Notz, established urologist, Düsseldorf. Creating love life without time pressure].

  MMW Fortschritte der Medizin 20091105

• Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.

  Annals of internal medicine 20091103

• Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.

  Annals of internal medicine 20091103

• Tadalafil (Adcirca) for pulmonary arterial hypertension.

  The Medical letter on drugs and therapeutics 20091102

• 2D and 3D DOSY 1H NMR, a useful tool for analysis of complex mixtures: application to herbal drugs or dietary supplements for erectile dysfunction.

  Journal of pharmaceutical and biomedical analysis 20091101

• [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

  Der Urologe. Ausg. A 20091101

• Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

  Diabetes care 20091101

• Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.

  Journal of pharmacological sciences 20091101

• Non-traumatic urologic emergencies in men: a clinical review.

  The western journal of emergency medicine 20091101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091101

• [Low-dose tadalafil improves arterial erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20091101

• High performance liquid chromatography-diode array and electrospray-mass spectrometry analysis of vardenafil, sildenafil, tadalafil, testosterone and local anesthetics in cosmetic creams sold on the Internet web sites.

  Journal of pharmaceutical and biomedical analysis 20091015

• Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

  European urology 20091001

• Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

  European urology 20091001

• Sclerosing lymphangitis of the penis after coadministration of tadalafil and fluconazole.

  Clinical and experimental dermatology 20091001

• Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.

  The Journal of pharmacology and experimental therapeutics 20091001

• Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study.

  The journal of sexual medicine 20091001

• Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.

  The journal of sexual medicine 20091001

• Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.

  Current medical research and opinion 20091001

• Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.

  La Radiologia medica 20091001

• Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.

  The Journal of rheumatology 20091001

• Pharmacotherapy of the overactive bladder.

  Discovery medicine 20091001

• Hair analysis to demonstrate administration of sildenafil to a woman in a case of drug-facilitated sexual assault.

  Journal of analytical toxicology 20091001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091001

• [Efficacy and safety of tadalafil for erectile dysfunction: an updated review].

  Zhonghua nan ke xue = National journal of andrology 20091001

• Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.

  Circulation 20090915

• Structural characterization of sulfoaildenafil, an analog of sildenafil.

  Journal of pharmaceutical and biomedical analysis 20090908

• The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.

  The journal of sexual medicine 20090901

• Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.

  Asian journal of andrology 20090901

• Penile rehabilitation.

  The American journal of nursing 20090901

• 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.

  The journal of sexual medicine 20090901

• Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

  Advances in therapy 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema.

  American journal of respiratory and critical care medicine 20090815

• Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

  BJU international 20090801

• Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.

  The Laryngoscope 20090801

• The burden and extent of comorbid conditions in patients with erectile dysfunction.

  International journal of clinical practice 20090801

• Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

  International journal of clinical practice 20090801

• Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction.

  International journal of clinical practice 20090801

• [Minute dose of tadalafil for nocturnal penile tumescence].

  Zhonghua nan ke xue = National journal of andrology 20090801

• High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.

  British journal of cancer 20090707

• [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

  Der Urologe. Ausg. A 20090701

• Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.

  Urology 20090701

• Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.

  Asian journal of andrology 20090701

• Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury.

  American journal of physiology. Heart and circulatory physiology 20090701

• Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.

  The journal of sexual medicine 20090701

• 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).

  The journal of sexual medicine 20090701

• [Effect of tadalafil therapy upon penile cavernous tissues in spontaneously hypertensive rats].

  Zhonghua yi xue za zhi 20090623

• Tadalafil therapy for pulmonary arterial hypertension.

  Circulation 20090609

• [Once daily therapy of erectile dysfunction. 'Flexible love life without time constraints'].

  MMW Fortschritte der Medizin 20090604

• Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue.

  Urology 20090601

• Vcsa1 acts as a marker of erectile function recovery after gene therapeutic and pharmacological interventions.

  The Journal of urology 20090601

• [Prospective evaluation of urology residents' interest in andrology].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20090601

• Tadalafil and purpura.

  The journal of sexual medicine 20090601

• Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

  Rheumatology (Oxford, England) 20090601

• From nature to drug discovery: the indole scaffold as a 'privileged structure'.

  Mini reviews in medicinal chemistry 20090601

• [Safety and tolerance of tadalafil in the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20090601

• By the way, doctor. Finasteride has been prescribed for my BPH. I think that the most frequent side effect is erectile dysfunction or loss of sexual desire. Would Levita or a similar drug (like Viagra or Cialis) overcome the side effects of finasteride?

  Harvard health letter 20090601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090601

• Prospective pharmacologic therapies for the overactive bladder.

  Therapeutic advances in urology 20090601

• Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.

  BJU international 20090501

• Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.

  BJU international 20090501

• Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.

  Diabetes care 20090501

• Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism.

  The journal of sexual medicine 20090501

• Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.

  The journal of sexual medicine 20090501

• Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model.

  The Journal of thoracic and cardiovascular surgery 20090501

• Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

  International journal of impotence research 20090501

• Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil.

  BJU international 20090501

• Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily.

  The journal of sexual medicine 20090501

• Detection of undeclared erectile dysfunction drugs and analogues in dietary supplements by ion mobility spectrometry.

  Journal of pharmaceutical and biomedical analysis 20090405

• Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.

  Clinical and experimental pharmacology & physiology 20090401

• EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.

  Neurological research 20090401

• Management of erectile dysfunction in general practice.

  The journal of sexual medicine 20090401

• Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen.

  Journal of applied physiology (Bethesda, Md. : 1985) 20090401

• Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction.

  Urology 20090401

• Retinal effects of 6 months of daily use of tadalafil or sildenafil.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20090401

• [Tadalafil for erectile dysfunction: efficacy evaluation].

  Zhonghua nan ke xue = National journal of andrology 20090401

• [Tadalafil (Cialis) after brain hemorrhage--basis for risk assessment is missing].

  Lakartidningen 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Transdermal delivery of tadalafil. I. Effect of vehicles on skin permeation.

  Drug development and industrial pharmacy 20090301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090301

• Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension.

  Korean circulation journal 20090301

• An unusual outbreak of hypoglycemia.

  The New England journal of medicine 20090212

• [Therapeutic effect of phosphodiesterase-5 inhibitor on pathological changes of tunica albuginea in erectile dysfunction: experiment with rats].

  Zhonghua yi xue za zhi 20090203

• Treatment of erectile dysfunction reduces psychological distress.

  International journal of andrology 20090201

• The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.

  BJU international 20090201

• Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.

  Pharmacology, biochemistry, and behavior 20090201

• Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.

  The journal of sexual medicine 20090201

• Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction.

  The journal of sexual medicine 20090201

• Isolation and structural elucidation of cyclopentynafil and N-octylnortadalafil found in a dietary supplement.

  Chemical & pharmaceutical bulletin 20090201

• Erectile dysfunction after therapy with metoprolol: the Hawthorne effect.

  Cardiology 20090101

• Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

  Psychopharmacology 20090101

• A placebo-controlled study of sildenafil effects on cognition in schizophrenia.

  Psychopharmacology 20090101

• Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.

  Expert opinion on investigational drugs 20090101

• Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.

  Current opinion in urology 20090101

• Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

  Acta pharmacologica Sinica 20090101

• Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.

  International journal of clinical practice 20090101

• Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

  Drug safety 20090101

• Modulators of arginine metabolism support cancer immunosurveillance.

  BMC immunology 20090101

• Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach.

  The journal of sexual medicine 20090101

• Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study.

  The journal of sexual medicine 20090101

• Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice.

  Respiratory research 20090101

• Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor?

  Journal of andrology 20090101

• Penile rehabilitation therapy with PDE-V inhibitors following radical prostatectomy: proceed with caution.

  Advances in urology 20090101

• [Tadalafil for erectile dysfunction: excellent safety and tolerance].

  Zhonghua nan ke xue = National journal of andrology 20090101

• Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.

  Journal of biological regulators and homeostatic agents 20090101

• [Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study].

  Urologiia (Moscow, Russia : 1999) 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• [Simultaneous determination of 8 illegal synthetic drugs in antihypertensive dietary supplements by high performance liquid chromatography-mass spectrometry].

  Se pu = Chinese journal of chromatography 20090101

• Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.

  PloS one 20090101

• Daily patterns of sexual intercourse attempts by men with erectile dysfunction treated with tadalafil: influence of age and marital status.

  International journal of impotence research 20090101

• Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily.

  International journal of impotence research 20090101

• Treatment of pediatric pulmonary hypertension.

  Vascular health and risk management 20090101

• Emerging treatments for premature ejaculation: focus on dapoxetine.

  Neuropsychiatric disease and treatment 20090101

• Association of PDE11A global haplotype with major depression and antidepressant drug response.

  Neuropsychiatric disease and treatment 20090101

• Effect of tadalafil on renal resistivity and pulsatility index in partial ureteral obstruction.

  Urologia internationalis 20090101

• [Cardiological aspects of tadalafil safety].

  Urologiia (Moscow, Russia : 1999) 20090101

• Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.

  Vascular health and risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Myopathy with concurrent tadalafil and simvastatin.

  Case reports in medicine 20090101

• Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

  BMC gastroenterology 20090101

• Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management.

  BMC musculoskeletal disorders 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090101

• Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.

  Arzneimittel-Forschung 20090101

• PDE5 inhibitors: in vitro and in vivo pharmacological profile.

  Current pharmaceutical design 20090101

• Phosphodiesterase type 5 inhibitors: unmet needs.

  Current pharmaceutical design 20090101

• Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment.

  Current pharmaceutical design 20090101

• PDE5 inhibitors in non-urological conditions.

  Current pharmaceutical design 20090101

• Phosphodiesterase-5 inhibitors: future perspectives.

  Current pharmaceutical design 20090101

• Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

  Drug design, development and therapy 20090101

• Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.

  Patient preference and adherence 20090101

• Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives.

  Patient preference and adherence 20090101

• Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.

  BMJ (Clinical research ed.) 20090101

• Therapeutic methods used in patients with Eisenmenger syndrome.

  Cardiology journal 20090101

• Sildenafil or vardenafil nonresponders' erectile response to tadalafil.

  Urology journal 20090101

• Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

  Clinical interventions in aging 20090101

• [Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application].

  Giornale italiano di cardiologia (2006) 20090101

• [Efficacy, safety and perspectives of tadalafil in a long-term once a day regimen in patients with erectile dysfunction].

  Urologiia (Moscow, Russia : 1999) 20090101

• Rehabilitation challenges in multiple sclerosis.

  Annals of Indian Academy of Neurology 20090101

• [Treatment of erectile dysfunction of neurogenic genesis with inhibitors of phosphodiesterase of type 5 in patients with diabetes mellitus].

  Urologiia (Moscow, Russia : 1999) 20090101

• Evaluation of therapeutic response of patients with erectile dysfunction.

  Medicinski arhiv 20090101

• Visual field loss after tadalafil: a case report.

  Acta ophthalmologica 20081201

• The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

  World journal of urology 20081201

• [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].

  Der Urologe. Ausg. A 20081201

• The role of combination medical therapy in benign prostatic hyperplasia.

  International journal of impotence research 20081201

• Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option.

  Current medical research and opinion 20081201

• [Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20081201

• [5-phosphodiesterase inhibitors and cardiovascular risk].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20081201

• ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

  International journal of chronic obstructive pulmonary disease 20081201

• Tadalafil in the treatment of erectile dysfunction.

  Therapeutics and clinical risk management 20081201

• Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20081101

• Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses.

  The journal of sexual medicine 20081101

• Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.

  Respirology (Carlton, Vic.) 20081101

• [Current aspects in epistaxis].

  HNO 20081101

• [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].

  Nihon rinsho. Japanese journal of clinical medicine 20081101

• Pulmonary embolism after tadalafil ingestion.

  Pharmacy world & science : PWS 20081001

• Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

  The Journal of urology 20081001

• Use of phosphodiesterase-5 inhibitors by college students.

  Revista de saude publica 20081001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• Erectile dysfunction in a murine model of sleep apnea.

  American journal of respiratory and critical care medicine 20080915

• Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction.

  The journal of sexual medicine 20080901

• The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men.

  The Journal of clinical endocrinology and metabolism 20080901

• Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.

  The journal of sexual medicine 20080901

• Pulmonary arterial hypertension: on the way to a manageable disease.

  Current opinion in investigational drugs (London, England : 2000) 20080901

• [Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080901

• Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.

  Clinical interventions in aging 20080901

• The use of phosphodiesterase 5 inhibitors with concomitant medications.

  Journal of endocrinological investigation 20080901

• [Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours].

  Zhonghua nan ke xue = National journal of andrology 20080901

• [Pulmonary arterial hypertension in Health District 11: a patient-oriented drug utilization analysis].

  Recenti progressi in medicina 20080901

• In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.

  Bioorganic & medicinal chemistry 20080815

• Methyl (11aS)-1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo-[3',4':1,2]pyridin[3,4-b]indol-2-substituted acetates: synthesis and three-dimensional quantitative structure-activity relationship investigation as a class of novel vasodilators.

  Journal of medicinal chemistry 20080814

• Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses.

  The journal of sexual medicine 20080801

• Enhancement of human sperm motility.

  The Journal of urology 20080801

• Structural elucidation of a tadalafil analogue found in a dietary supplement.

  Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan 20080801

• Daily Tadalafil: line extension. Beware medicalisation of human existence.

  Prescrire international 20080801

• The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues.

  The journal of sexual medicine 20080701

• Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study.

  The journal of sexual medicine 20080701

• Psychosocial impact and effectiveness of tadalafil among treatment-naïve and previously-treated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries.

  Current medical research and opinion 20080701

• Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.

  Pakistan journal of pharmaceutical sciences 20080701

• Can Viagra really cause hearing and vision loss? If so, is this a reason to avoid using it?

  Mayo Clinic health letter (English ed.) 20080701

• [Transient global amnesia after tadalafil use].

  Medicina clinica 20080614

• Alternate-day tadalafil in the management of honeymoon impotence.

  The journal of sexual medicine 20080601

• Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.

  British journal of pharmacology 20080601

• [Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080601

• Analysis of illegally manufactured formulations of tadalafil (Cialis) by 1H NMR, 2D DOSY 1H NMR and Raman spectroscopy.

  Journal of pharmaceutical and biomedical analysis 20080512

• An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study.

  European urology 20080501

• Re: Wayne J.G. Hellstrom, Marc Gittelman, Jonathan Jarow, et al. an evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008;53:1058-65.

  European urology 20080501

• The effects of tadalafil on axial-pattern skin flap survival in rats.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20080501

• The triad of erectile dysfunction, hypogonadism and the metabolic syndrome.

  International journal of clinical practice 20080501

• Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

  Journal of clinical pharmacology 20080501

• Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.

  The journal of sexual medicine 20080501

• Tadalafil improves oxygenation in a model of newborn pulmonary hypertension.

  Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 20080501

• [Treatment of male erectile dysfunction following spinal cord injuries using PDE5 inhibitors].

  Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti 20080501

• Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.

  International journal of cardiology 20080425

• Intracerebral hemorrhage associated with use of tadalafil (Cialis).

  Neurology 20080408

• Tadalafil (Cialis) once a day for erectile dysfunction.

  The Medical letter on drugs and therapeutics 20080407

• Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil.

  The Journal of pharmacology and experimental therapeutics 20080401

• Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.

  The journal of sexual medicine 20080401

• Evidence supportive of impaired myocardial blood flow reserve at high altitude in subjects developing high-altitude pulmonary edema.

  American journal of physiology. Heart and circulatory physiology 20080401

• Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches.

  Journal of analytical toxicology 20080401

• [Evaluation of tadalafil for the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20080401

• Role of phosphodiesterase 5 in synaptic plasticity and memory.

  Neuropsychiatric disease and treatment 20080401

• Identification of a novel vardenafil analogue in herbal product.

  Journal of pharmaceutical and biomedical analysis 20080313

• Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.

  European urology 20080301

• Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States.

  The journal of sexual medicine 20080301

• Lower urinary tract symptoms and sexual dysfunction: a common approach.

  BJU international 20080301

• Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness.

  Chest 20080301

• Inflatable penile prostheses for the treatment of erectile dysfunction: an update.

  Expert review of medical devices 20080301

• Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.

  Urology 20080301

• Effect of tadalafil on anaerobic performance indices in healthy athletes.

  British journal of sports medicine 20080201

• The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' VO2max, aerobic, and anaerobic thresholds in normoxia.

  International journal of sports medicine 20080201

• cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil.

  BJU international 20080201

• Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation.

  The Journal of urology 20080201

• Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.

  The journal of sexual medicine 20080201

• Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.

  Current diabetes reviews 20080201

• Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.

  Diabetic medicine : a journal of the British Diabetic Association 20080201

• Phosphodiesterase 5 inhibition in essential hypertension.

  Current hypertension reports 20080201

• Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction.

  Atherosclerosis 20080101

• Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects.

  Eye (London, England) 20080101

• Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease.

  International journal of impotence research 20080101

• Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease.

  International journal of impotence research 20080101

• Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection.

  BJU international 20080101

• Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.

  Journal of andrology 20080101

• The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction.

  International journal of impotence research 20080101

• Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

  The Annals of pharmacotherapy 20080101

• The cardiovascular safety of tadalafil.

  Expert opinion on drug safety 20080101

• Looking to the future for erectile dysfunction therapies.

  Drugs 20080101

• Inhibition of hyaluronan export reduces collagen degradation in interleukin-1 treated cartilage.

  Arthritis research & therapy 20080101

• Influence of the incremental step size in work rate on exercise response and gas exchange in patients with pulmonary hypertension.

  BMC pulmonary medicine 20080101

• Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.

  Urologia internationalis 20080101

• Discovery of NO in the penis.

  International journal of impotence research 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.

  International journal of impotence research 20080101

• Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.

  Clinical hemorheology and microcirculation 20080101

• Drugs used to treat erectile dysfunction.

  Orthopedic nursing 20080101

• Daily tadalafil prevents erectile dysfunction in diabetic men.

  Medscape journal of medicine 20080101

• Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy.

  Advances in urology 20080101

• [Treatment of erectile dysfunction in patients with plastic induration of the penis].

  Urologiia (Moscow, Russia : 1999) 20080101

• Structure -activity relationships of PDE5 inhibitors.

  Current medicinal chemistry 20080101

• Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial.

  BMC musculoskeletal disorders 20080101

• The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.

  Reviews in cardiovascular medicine 20080101

• Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.

  International journal of impotence research 20080101

• Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment.

  Wilderness & environmental medicine 20080101

• Sickle cell trait and priapism: a case report and review of the literature.

  Cases journal 20080101

• Phosphodiesterase type-5 inhibitor and oxidative stress.

  International journal of immunopathology and pharmacology 20080101

• Markers of erectile dysfunction.

  Indian journal of urology : IJU : journal of the Urological Society of India 20080101

• Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

  Patient preference and adherence 20080101

• Reverse phase high performance liquid chromatographic method for the analysis of letrozole in pharmaceutical dosage forms.

  Indian journal of pharmaceutical sciences 20080101

• Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion.

  Annals of pediatric cardiology 20080101

• Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

  Current oncology (Toronto, Ont.) 20071201

• Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial.

  Urology 20071201

• Novel phosphodiesterase-5 inhibitors: current indications and future directions.

  Indian journal of medical sciences 20071201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071201

• Review of bosentan in the management of pulmonary arterial hypertension.

  Vascular health and risk management 20071201

• Treating COPD with PDE 4 inhibitors.

  International journal of chronic obstructive pulmonary disease 20071201

• Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.

  Biochemistry 20071127

• Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?

  Journal of the neurological sciences 20071115

• Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.

  The Journal of pharmacology and experimental therapeutics 20071101

• Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury.

  Archives of neurology 20071101

• Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.

  International journal of clinical practice 20071101

• Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.

  Asian journal of andrology 20071101

• Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men.

  Fertility and sterility 20071001

• Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.

  Neurourology and urodynamics 20071001

• Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects.

  Journal of clinical pharmacology 20071001

• Analogues of erectile dysfunction drugs: an under-recognised threat.

  Hong Kong medical journal = Xianggang yi xue za zhi 20071001

• Expert opinion on available options treating pulmonary arterial hypertension.

  Expert opinion on pharmacotherapy 20071001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071001

• N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization.

  Biochemistry 20070911

• [PDE5 inhibitors. A new option in the treatment of ureteral colic?].

  Der Urologe. Ausg. A 20070901

• [PDE5 inhibitors in treatment of benign prostatic syndrome].

  Der Urologe. Ausg. A 20070901

• Protective effect of endothelial nitric oxide synthase against induction of chemically-induced diabetes in mice.

  Nitric oxide : biology and chemistry 20070901

• [Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20070901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070901

• Chiral separation of two pairs of enantiomers of tadalafil by high-performance liquid chromatography.

  Journal of chromatographic science 20070901

• [Novel indications for phosphodiesterase type 5 inhibitors].

  Medizinische Klinik (Munich, Germany : 1983) 20070815

• Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction.

  Chest 20070801

• Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.

  The Journal of rheumatology 20070801

• [The safety of tadalafil in the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20070801

• Mondor's phlebitis after using tadalafil.

  The British journal of dermatology 20070701

• Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.

  BJU international 20070701

• Validated liquid chromatographic-ultraviolet method for the quantitation of tadalafil in human plasma using liquid-liquid extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601

• Tadalafil population pharmacokinetics in patients with erectile dysfunction.

  European journal of clinical pharmacology 20070601

• Confusion still reigns in premature ejaculation management.

  International journal of clinical practice 20070601

• [Efficacy of tadalafil for erectile dysfunction: an updated review].

  Zhonghua nan ke xue = National journal of andrology 20070601

• Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus.

  Vojnosanitetski pregled 20070601

• Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation.

  Therapeutics and clinical risk management 20070601

• A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction.

  The journal of sexual medicine 20070501

• Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.

  Asian journal of andrology 20070501

• The future of the oral pharmacotherapy of male erectile dysfunction: things to come.

  Expert opinion on emerging drugs 20070501

• Reducing the incidence of high-altitude pulmonary edema.

  Annals of internal medicine 20070417

• The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.

  Clinical pharmacology and therapeutics 20070401

• Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.

  BJU international 20070401

• Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  The Journal of urology 20070401

• Comet tails in high-altitude pulmonary edema: diagnostic portent or streak in the sky?

  Chest 20070401

• Oral phosphodiesterase-5 inhibitors: effect of heme oxygenase inhibition on cGMP signalling in rat cavernous tissue.

  Andrologia 20070401

• Characterization and functional role of androgen-dependent PDE5 activity in the bladder.

  Endocrinology 20070301

• Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.

  British journal of pharmacology 20070301

• Quality of life in HIV clinical trials: why sexual health must not be ignored.

  PLoS clinical trials 20070301

• [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20070301

• [Advances in the studies on the safety of tadalafil in treating erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20070301

• Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease.

  The Korean journal of internal medicine 20070301

• Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.

  Spinal cord 20070201

• Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).

  European urology 20070201

• In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.

  Urological research 20070201

• PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.

  Bioorganic & medicinal chemistry letters 20070201

• The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.

  BJU international 20070201

• Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.

  British journal of pharmacology 20070201

• Tadalafil as an in vitro sperm motility stimulant.

  Andrologia 20070201

• Tadalafil for treatment of erectile dysfunction in men on antidepressants.

  Journal of clinical psychopharmacology 20070201

• An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.

  BJU international 20070201

• A review of pulmonary arterial hypertension: role of ambrisentan.

  Vascular health and risk management 20070201

• Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.

  The Cochrane database of systematic reviews 20070124

• Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS).

  International journal of impotence research 20070101

• Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.

  International journal of impotence research 20070101

• The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.

  International journal of impotence research 20070101

• The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.

  International journal of impotence research 20070101

• Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

  British journal of clinical pharmacology 20070101

• Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US.

  International journal of impotence research 20070101

• Gene therapy and erectile dysfunction: the current status.

  Asian journal of andrology 20070101

• Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study.

  International journal of impotence research 20070101

• Phosphodiesterase type 5 inhibitors: the day after.

  European urology 20070101

• The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.

  International journal of impotence research 20070101

• Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

  Frontiers in bioscience : a journal and virtual library 20070101

• Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart.

  International journal of impotence research 20070101

• Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

  International journal of impotence research 20070101

• PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.

  The European respiratory journal 20070101

• The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study.

  BJU international 20070101

• Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.

  The journal of sexual medicine 20070101

• Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.

  Medical hypotheses 20070101

• Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

  Cardiology in review 20070101

• The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels.

  Current topics in medicinal chemistry 20070101

• Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report.

  Journal of medical case reports 20070101

• PDE5 inhibitors beyond erectile dysfunction.

  International journal of impotence research 20070101

• The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development.

  Current medicinal chemistry 20070101

• [Drug counterfeiting--the risk to the public health].

  Przeglad lekarski 20070101

• Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.

  PloS one 20070101

• Cavernous body reduction in four patients with erectile dysfunction due to insufficient venous occlusion and a deficit of elastic fibers in the tunica albuginea.

  International braz j urol : official journal of the Brazilian Society of Urology 20070101

• [Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension].

  Kardiologiia 20070101

• Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients.

  Indian heart journal 20070101

• Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.

  Indian heart journal 20070101

• Oral tadalafil in pulmonary artery hypertension: a prospective study.

  Indian heart journal 20070101

• Premature ejaculation.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• The new patent regime: Implications for patients in India.

  Indian journal of psychiatry 20070101

• Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

  Core evidence 20070101

• Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectives.

  Drug target insights 20070101

• [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].

  Deutsche medizinische Wochenschrift (1946) 20061208

• [Short history of erectile dysfunction treatment].

  Revue medicale suisse 20061206

• Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.

  European urology 20061201

• Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.

  BJU international 20061201

• [Tadalafil and patients preference in the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20061201

• Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment.

  Minerva endocrinologica 20061201

• Comorbid LUTS and erectile dysfunction: optimizing their management.

  Current medical research and opinion 20061201

• Sexual function in hypertensive patients receiving treatment.

  Vascular health and risk management 20061201

• Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

  Clinical interventions in aging 20061201

• New agents in the treatment of premature ejaculation.

  Neuropsychiatric disease and treatment 20061201

• Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.

  The Journal of experimental medicine 20061127

• [Viagra -- patients stand by their treatment].

  Praxis 20061122

• Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.

  Brain research 20061106

• Regaining of morning erection and sexual confidence in patients with erectile dysfunction.

  Asian journal of andrology 20061101

• Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study.

  Asian journal of andrology 20061101

• A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.

  Molecular pharmacology 20061101

• Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.

  European urology 20061101

• Detection of sildenafil analogues in herbal products for erectile dysfunction.

  Journal of toxicology and environmental health. Part A 20061101

• Tadalafil associated with typical migraine aura without headache.

  Cephalalgia : an international journal of headache 20061101

• The effect of tadalafil on psychosocial outcomes in Swedish men with erectile distress: a multicentre, non-randomised, open-label clinical study.

  International journal of clinical practice 20061101

• Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.

  The journal of sexual medicine 20061101

• Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.

  The journal of sexual medicine 20061101

• The economic effect of switching from sildenafil to another phosphodiesterase type 5 inhibitor.

  Managed care interface 20061101

• Tadalafil as treatment for idiopathic pulmonary arterial hypertension.

  Arquivos brasileiros de cardiologia 20061101

• Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.

  Circulation 20061024

• Summaries for patients. A comparison of medications used to prevent high-altitude pulmonary edema.

  Annals of internal medicine 20061003

• Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial.

  Annals of internal medicine 20061003

• Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.

  International journal of andrology 20061001

• A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.

  International journal of radiation oncology, biology, physics 20061001

• An epidemiological and knowledge, attitudes, beliefs and practices study of sexually transmitted infections in older men.

  Singapore medical journal 20061001

• Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.

  Urology 20061001

• Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study.

  Urology 20061001

• Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.

  The Canadian journal of urology 20061001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061001

• Effects of tadalafil on myocardial blood flow in patients with coronary artery disease.

  Coronary artery disease 20060901

• Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.

  BJU international 20060901

• Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

  British journal of clinical pharmacology 20060901

• Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.

  The journal of sexual medicine 20060901

• Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

  Pharmacological reviews 20060901

• Through the eyes of women: the partners' perspective on tadalafil.

  Urology 20060901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060901

• [Efficacy and safety of two dosing regimens with Tadalafil in Spanish men with erectile dysfunction: results from the SURE study in 14 European countries].

  Actas urologicas espanolas 20060901

• Visual loss with erectile dysfunction medications.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060815

• Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.

  BJU international 20060801

• Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  European urology 20060801

• Comparison of phosphodiesterase type 5 (PDE5) inhibitors.

  International journal of clinical practice 20060801

• Treatment of erectile dysfunction with chronic dosing of tadalafil.

  European urology 20060801

• Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

  Expert opinion on drug metabolism & toxicology 20060801

• Phosphodiesterases in the CNS: targets for drug development.

  Nature reviews. Drug discovery 20060801

• Phosphodiesterase-5 inhibitors and their hemodynamic effects.

  Current hypertension reports 20060801

• Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.

  Urology 20060801

• Erectile dysfunction.

  Harvard men's health watch 20060801

• Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.

  The Journal of biological chemistry 20060728

• [Phosphodiesterase inhibitors: effectiveness and new applications].

  Nederlands tijdschrift voor geneeskunde 20060722

• [Effectiveness duration determines selection].

  MMW Fortschritte der Medizin 20060720

• Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum.

  European journal of pharmacology 20060717

• Treatment strategy for 'non-responders' to tadalafil and vardenafil: a real-life study.

  European urology 20060701

• A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia.

  Nature genetics 20060701

• NAION and treatment of erectile dysfunction: reply from Pfizer.

  The British journal of ophthalmology 20060701

• Tadalafil-induced subretinal and choroidal hemorrhage in a patient with an unsuspected uveal (choroidal and ciliary body) melanoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20060701

• Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.

  The journal of sexual medicine 20060701

• Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.

  The journal of sexual medicine 20060701

• Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.

  The journal of sexual medicine 20060701

• Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction.

  International journal of clinical practice 20060701

• Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.

  The American journal of cardiology 20060615

• Advertising in medical journals: should current practices change?

  PLoS medicine 20060601

• Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.

  Urology 20060601

• Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men.

  International journal of urology : official journal of the Japanese Urological Association 20060601

• Erectile dysfunction.

  Clinical evidence 20060601

• Application of LC-ESI-MS-MS for detection of synthetic adulterants in herbal remedies.

  Journal of pharmaceutical and biomedical analysis 20060503

• Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.

  European urology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Structural elucidation of a tadalafil analogue found as an adulterant of a herbal product.

  Food additives and contaminants 20060501

• Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat.

  The journal of sexual medicine 20060501

• Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design.

  The journal of sexual medicine 20060501

• Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction.

  The journal of sexual medicine 20060501

• Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries.

  The journal of sexual medicine 20060501

• Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.

  Urology 20060501

• [Observation of safety and efficacy of tadalafil for men with erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20060501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060501

• Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.

  International journal of cardiology 20060414

• Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study.

  Andrologia 20060401

• Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog.

  Journal of veterinary medicine. A, Physiology, pathology, clinical medicine 20060401

• 'Sex for life'? Men's counter-stories on 'erectile dysfunction', male sexuality and ageing.

  Sociology of health & illness 20060401

• Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.

  International journal of clinical practice 20060401

• [Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations--the patient should be given the opportunity to try out all three].

  Lakartidningen 20060401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060401

• Tadalafil pharmacokinetics in healthy subjects.

  British journal of clinical pharmacology 20060301

• Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil.

  The journal of sexual medicine 20060301

• Ophthalmic aspects of erectile dysfunction drugs.

  American journal of ophthalmology 20060301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060301

• Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography-electrospray ionization tandem mass spectrometry.

  Journal of chromatography. A 20060203

• Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.

  The Journal of pharmacology and experimental therapeutics 20060201

• Platelet count and function at high altitude and in high-altitude pulmonary edema.

  Journal of applied physiology (Bethesda, Md. : 1985) 20060201

• Can erectile dysfunction drug use lead to ischaemic optic neuropathy?

  The British journal of ophthalmology 20060201

• Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction.

  The British journal of ophthalmology 20060201

• PDE5 inhibitors: are there differences?

  The Canadian journal of urology 20060201

• Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide.

  European journal of pharmacology 20060113

• Epistaxis after PDE-5 inhibitors misuse.

  International journal of impotence research 20060101

• Tadalafil reversal of sexual dysfunction caused by serotonin enhancing medications in women.

  Journal of sex & marital therapy 20060101

• Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.

  International journal of impotence research 20060101

• Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.

  European urology 20060101

• Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.

  International journal of impotence research 20060101

• Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.

  The Annals of thoracic surgery 20060101

• How new drugs help treat erectile dysfunction.

  Nursing 20060101

• Phosphodiesterase 11: a brief review of structure, expression and function.

  International journal of impotence research 20060101

• The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine.

  The journal of sexual medicine 20060101

• Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells.

  The journal of sexual medicine 20060101

• Beyond Viagra. What are your options?

  Mayo Clinic health letter (English ed.) 20060101

• Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.

  Drugs & aging 20060101

• Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction.

  International journal of impotence research 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• [Treatment of erectile dysfunction after nerve-preserving radical retropubic prostatectomy].

  Urologiia (Moscow, Russia : 1999) 20060101

• [Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study].

  Actas urologicas espanolas 20060101

• A comparative review of apomorphine formulations for erectile dysfunction : recommendations for use in the elderly.

  Drugs & aging 20060101

• Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices.

  Rapid communications in mass spectrometry : RCM 20060101

• Phosphodiesterase inhibitors in Raynaud's phenomenon.

  The Annals of pharmacotherapy 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles.

  Current pharmaceutical design 20060101

• Cardiovascular effects of phosphodiesterase 5 inhibitors.

  Current pharmaceutical design 20060101

• Electrospray tandem mass spectrometric investigations of tadalafil and its analogue.

  Rapid communications in mass spectrometry : RCM 20060101

• Cutaneous reaction to drugs used for erectile dysfunction: case report and review of the literature.

  Journal of cutaneous medicine and surgery 20060101

• [Recognizing difference: the challenge of ethnopsychiatry].

  Sante mentale au Quebec 20060101

• Tadalafil in the management of severe pulmonary artery hypertension.

  Indian heart journal 20060101

• Angioneurotic oedema with tadalafil: A rare case report.

  Indian journal of psychiatry 20060101

• Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.

  The American journal of cardiology 20051226

• Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.

  The American journal of cardiology 20051226

• Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.

  The American journal of cardiology 20051226

• Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.

  The American journal of cardiology 20051226

• Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

  The American journal of cardiology 20051226

• The therapeutic dilemma: how to use tadalafil.

  International journal of andrology 20051201

• Phosphodiesterase inhibitors in female sexual dysfunction.

  World journal of urology 20051201

• Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

  World journal of urology 20051201

• Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.

  World journal of urology 20051201

• An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.

  BJU international 20051201

• Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship?

  Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20051201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051201

• Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials.

  Journal of affective disorders 20051101

• The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease.

  British journal of clinical pharmacology 20051101

• Efficacy and safety of tadalafil in men with severe erectile dysfunction in tertiary care academic centers.

  Current urology reports 20051101

• Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.

  Digestive diseases and sciences 20051101

• PDE-5 inhibitors: current status and future trends.

  The Urologic clinics of North America 20051101

• The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials.

  Current medical research and opinion 20051101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051101

• Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.

  The journal of sexual medicine 20051101

• Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials.

  The Journal of urology 20051001

• Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.

  The Journal of urology 20051001

• [Therapy for organic erectile dysfunction].

  Der Urologe. Ausg. A 20051001

• Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials.

  BJU international 20051001

• Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology.

  Neuro endocrinology letters 20051001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051001

• High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.

  Biochemical and biophysical research communications 20050902

• The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

  Journal of clinical pharmacology 20050901

• [Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].

  Zhonghua nan ke xue = National journal of andrology 20050901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050901

• Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries.

  The journal of sexual medicine 20050901

• Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial.

  The journal of sexual medicine 20050901

• The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.

  Journal of the American College of Cardiology 20050816

• Making a silk purse out of a sow's ear.

  Journal of the American College of Cardiology 20050816

• Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050805

• Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil.

  European urology 20050801

• Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.

  The Journal of urology 20050801

• Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.

  The Journal of urology 20050801

• Phosphodiesterase type 5 inhibitors for erectile dysfunction.

  BJU international 20050801

• Tadalafil-associated priapism.

  Urology 20050801

• [Instructions for the combination of PDE5 inhibitors with alpha-blockers].

  Zhonghua nan ke xue = National journal of andrology 20050801

• Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

  The American journal of cardiology 20050715

• [Quality assurance in the urologist's practice. Erectile dysfunction as an example of a multicenter approach to documenting treatment results].

  Der Urologe. Ausg. A 20050701

• [Update of PDE5 inhibitors as treatment of ED].

  Zhonghua nan ke xue = National journal of andrology 20050701

• Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction.

  The journal of sexual medicine 20050701

• The efficacy of tadalafil in clinical populations.

  The journal of sexual medicine 20050701

• Tadalafil-associated anterior ischaemic optic neuropathy.

  Eye (London, England) 20050601

• An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.

  European urology 20050601

• [Erectile dysfunction (ED) and diabetes mellitus].

  Nihon rinsho. Japanese journal of clinical medicine 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.

  Bioorganic & medicinal chemistry letters 20050502

• Viagra and anterior ischemic optic neuropathy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20050501

• Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.

  Microvascular research 20050501

• Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.

  Expert opinion on drug safety 20050501

• Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction.

  The journal of sexual medicine 20050501

• Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.

  Nature clinical practice. Urology 20050501

• [Your patient wants to go to the mountains. You protect him from mountain sickness and altitude edema].

  MMW Fortschritte der Medizin 20050407

• Tadalafil in a patient with treatment-resistant depression and antidepressant polypharmacy.

  Journal of clinical psychopharmacology 20050401

• Viagra, Levitra, and Cialis: what's the difference?

  South Dakota journal of medicine 20050401

• Erectile dysfunction: the Viagra revolution.

  Harvard men's health watch 20050401

• Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction.

  Journal of medicinal chemistry 20050324

• Effects of high altitude exposure on cerebral hemodynamics in normal subjects.

  Stroke 20050301

• Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.

  European urology 20050301

• Clinical monograph for drug formulary review: erectile dysfunction agents.

  Journal of managed care pharmacy : JMCP 20050301

• Tadalafil associated with anterior ischemic optic neuropathy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20050301

• Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20050301

• ED drugs covered, but managed care unmoved.

  Managed care (Langhorne, Pa.) 20050301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050301

• Recurrent epistaxis after treatment with tadalafil (Cialis).

  Acta oto-laryngologica 20050301

• Simultaneous determination of sildenafil, vardenafil and tadalafil as forbidden components in natural dietary supplements for male sexual potency by high-performance liquid chromatography-electrospray ionization mass spectrometry.

  Journal of chromatography. A 20050225

• Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.

  Molecular human reproduction 20050201

• Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.

  European urology 20050201

• Erectile dysfunction and cardiovascular disease.

  Mayo Clinic proceedings 20050201

• Patient education series. Erectile dysfunction.

  Nursing 20050201

• Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.

  Urology 20050201

• A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men.

  International journal of clinical practice 20050201

• Determination of tadalafil in pharmaceutical preparation by HPLC using monolithic silica column.

  Talanta 20050115

• cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.

  Circulation research 20050107

• Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial.

  International journal of impotence research 20050101

• High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.

  International journal of impotence research 20050101

• Interaction between tadalafil and itraconazole.

  The Annals of pharmacotherapy 20050101

• Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.

  Clinical pharmacology and therapeutics 20050101

• From aspiration to achievement: assessment and noninvasive treatment of erectile dysfunction in aging men.

  Journal of the American Geriatrics Society 20050101

• Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?

  International journal of impotence research 20050101

• Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.

  Expert opinion on pharmacotherapy 20050101

• Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.

  Expert opinion on pharmacotherapy 20050101

• Recreational use and misuse of phosphodiesterase 5 inhibitors.

  Journal of the American Pharmacists Association : JAPhA 20050101

• Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.

  Archives of andrology 20050101

• 3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.

  International journal of impotence research 20050101

• Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.

  Journal of andrology 20050101

• Phosphodiesterase 5 inhibitors for erectile dysfunction.

  The Annals of pharmacotherapy 20050101

• Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy.

  International journal of impotence research 20050101

• Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.

  Respiratory research 20050101

• A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia.

  International journal of impotence research 20050101

• New achievement and novel therapeutic applications of PDE5 inhibithors in older males.

  Journal of endocrinological investigation 20050101

• A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

  Drugs 20050101

• Phosphodiesterase 11 (PDE11): is it a player in human testicular function?

  International journal of impotence research 20050101

• Available and future treatments for erectile dysfunction.

  Clinical cornerstone 20050101

• The efficacy and safety of PDE5 inhibitors.

  Clinical cornerstone 20050101

• Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.

  Clinical cornerstone 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.

  Drugs & aging 20050101

• Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.

  Drugs 20050101

• [An evidence-based approach to writing reviews as illustrated by treatment of erectile dysfunction].

  Urologiia (Moscow, Russia : 1999) 20050101

• Hypnosis-associated blue-tinted vision: a case report.

  BMC ophthalmology 20050101

• Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction.

  BMC urology 20050101

• Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.

  Current pharmaceutical design 20050101

• FDA updates labeling for erectile dysfunction drugs.

  FDA consumer 20050101

• In that case.

  Journal of bioethical inquiry 20050101

• There have been inadequate warnings that erectile dysfunction drugs can cause blindness.

  MedGenMed : Medscape general medicine 20050101

• PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.

  Reviews in urology 20050101

• Coital hemorrhage of an arteriovenous malformation after premedication with tadalafil (Cialis).

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20050101

• Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.

  Current urology reports 20041201

• Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies.

  Current urology reports 20041201

• Structural basis for the activity of drugs that inhibit phosphodiesterases.

  Structure (London, England : 1993) 20041201

• Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects.

  Methods and findings in experimental and clinical pharmacology 20041201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041201

• Premature ejaculation. 3. Therapy.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20041201

• Development of a Micellar electrokinetic capillary chromatography method for the determination of three drugs employed in the erectile dysfunction therapy.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041125

• Analysis of undeclared synthetic phosphodiesterase-5 inhibitors in dietary supplements and herbal matrices by LC-ESI-MS and LC-UV.

  Journal of pharmaceutical and biomedical analysis 20041115

• Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.

  Circulation 20041109

• Tadalafil in primary pulmonary arterial hypertension.

  Annals of internal medicine 20041102

• Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients.

  Spinal cord 20041101

• New phosphodiesterase inhibitors in the treatment of erectile dysfunction.

  Expert opinion on pharmacotherapy 20041101

• Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

  The Journal of urology 20041101

• Tadalafil and palpebral edema.

  Southern medical journal 20041101

• Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.

  Diabetologia 20041101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041101

• Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.

  The journal of sexual medicine 20041101

• Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.

  The journal of sexual medicine 20041101

• Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.

  European journal of pharmacology 20041019

• Strategies for managing sexual dysfunction induced by antidepressant medication.

  The Cochrane database of systematic reviews 20041018

• Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

  Journal of the American College of Cardiology 20041006

• Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041005

• Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.

  World journal of urology 20041001

• Nocturnal electrobioimpedance volumetric assessment in diabetic men with erectile dysfunction before and after tadalafil intake.

  International journal of impotence research 20041001

• Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.

  BJU international 20041001

• Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction.

  Urology 20041001

• Specific aspects of erectile dysfunction in spinal cord injury.

  International journal of impotence research 20041001

• Erectile dysfunction.

  RN 20041001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041001

• Counterfeits of impotence drug appear in the United Kingdom.

  BMJ (Clinical research ed.) 20040904

• Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction.

  European urology 20040901

• Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial.

  The Journal of urology 20040901

• Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels.

  Clinical endocrinology 20040901

• Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events.

  The journal of sexual medicine 20040901

• Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study.

  The journal of sexual medicine 20040901

• Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study.

  The journal of sexual medicine 20040901

• [Support permanent discount for Viagra and Cialis in MS! Specified subsidy according to the Danish model is justified].

  Lakartidningen 20040826

• The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.

  The Journal of urology 20040801

• Population dose-response model for tadalafil in the treatment of male erectile dysfunction.

  Pharmaceutical research 20040801

• Structure elucidation of sildenafil analogues in herbal products.

  Food additives and contaminants 20040801

• [Birthday of a 'potency pill'. Helmut Newton celebrates posthumously likewise].

  MMW Fortschritte der Medizin 20040722

• Tadalafil (Cialis) for erectile dysfunction.

  American family physician 20040715

• [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].

  Der Urologe. Ausg. A 20040701

• Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

  Molecular pharmacology 20040701

• New oral drugs for erectile dysfunction.

  Drug and therapeutics bulletin 20040701

• My doctor prescribed Cialis [tadalafil] for erectile dysfunction. Anything I need to watch out for? I have a heart condition.

  Heart advisor 20040701

• Time course of the interaction between tadalafil and nitrates.

  Journal of the American College of Cardiology 20040602

• Re: tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

  The Journal of urology 20040601

• The efficacy and safety of tadalafil: an update.

  BJU international 20040601

• A consumer's guide to impotence drugs.

  The Johns Hopkins medical letter health after 50 20040601

• Potency, selectivity, and consequences of nonselectivity of PDE inhibition.

  International journal of impotence research 20040601

• [Erectile function disorders. Epidemiology, physiology, etiology, diagnosis and therapy].

  Der Nervenarzt 20040601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040601

• [New options in the treatment of various forms of diabetic neuropathy].

  MMW Fortschritte der Medizin 20040520

• [After taking the table, immediate sex? New potency pill allows more time for love life].

  MMW Fortschritte der Medizin 20040506

• Emerging oral drugs for erectile dysfunction.

  Expert opinion on emerging drugs 20040501

• [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].

  MMW Fortschritte der Medizin 20040415

• [ED (erectile dysfunction) therapy in general practice. Increased patient satisfaction].

  MMW Fortschritte der Medizin 20040415

• A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.

  European urology 20040401

• Treatment of erectile dysfunction.

  International journal of STD & AIDS 20040401

• Pills for erectile dysfunction: now there are three.

  Harvard men's health watch 20040401

• Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.

  Clinical cardiology 20040401

• Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.

  Clinical cardiology 20040401

• Tadalafil and vardenafil.

  Nature reviews. Drug discovery 20040401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040401

• [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].

  Zhonghua nan ke xue = National journal of andrology 20040401

• Sexual dysfunction and diabetes.

  International journal of clinical practice 20040401

• Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.

  AIDS treatment news 20040326

• Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.

  European urology 20040301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040301

• Therapeutic options for patients returning to sexual activity.

  The Journal of the American Osteopathic Association 20040301

• Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.

  The Journal of the American Osteopathic Association 20040301

• [Treatment of erectile dysfunction].

  Orvosi hetilap 20040227

• Cialis is here. The soft sell.

  Newsweek 20040202

• Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

  Journal of molecular and cellular cardiology 20040201

• [Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].

  Der Urologe. Ausg. A 20040201

• Tadalafil (Cialis) and vardenafil (Levitra) recently approved drugs for erectile dysfunction.

  Urologic nursing 20040201

• Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.

  Harvard health letter 20040101

• Third drug for impotence.

  FDA consumer 20040101

• New drugs of 2003.

  Journal of the American Pharmacists Association : JAPhA 20040101

• Therapy of ED: PDE-5 Inhibitors.

  Endocrine 20040101

• [Old and new treatments of erectile dysfunction].

  Duodecim; laaketieteellinen aikakauskirja 20040101

• Erectile dysfunction: evaluation and new treatment options.

  Psychosomatic medicine 20040101

• Interactions between grapefruit juice and cardiovascular drugs.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.

  Medical hypotheses 20040101

• New treatment options for erectile dysfunction in patients with diabetes mellitus.

  Drugs 20040101

• Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.

  The American journal of geriatric cardiology 20040101

• [Viagra, cialis, impase--which of them, to whom, when and how?].

  Urologiia (Moscow, Russia : 1999) 20040101

• [Influence of gender on clinical research].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101

• New tools 2004.

  Diabetes self-management 20040101

• Pharmacotherapy of sexual dysfunctions : current status.

  Indian journal of psychiatry 20040101

• Tadalafil (cialis) for erectile dysfunction.

  The Medical letter on drugs and therapeutics 20031222

• Tadalafil for the treatment of erectile dysfunction.

  Current urology reports 20031201

• Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.

  Current urology reports 20031201

• Tadalafil in the treatment of erectile dysfunction.

  Current urology reports 20031201

• Oral drug treatment of erectile dysfunction.

  International journal of impotence research 20031201

• Tadalafil: new preparation. Slightly more convenient, but poorly assessed in organic disorders.

  Prescrire international 20031201

• Cialis.

  Discovery medicine 20031201

• Time course of the interaction between tadalafil and nitrates.

  Journal of the American College of Cardiology 20031119

• [Pleasure and pain in sexual relations. The basis and reasons for sex counseling by the general practitioner].

  MMW Fortschritte der Medizin 20031113

• Overview of phosphodiesterase 5 inhibition in erectile dysfunction.

  The American journal of cardiology 20031106

• Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.

  The American journal of cardiology 20031106

• Cardiovascular effects of tadalafil.

  The American journal of cardiology 20031106

• Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.

  The American journal of cardiology 20031106

• Roundtable discussion: tadalafil study group.

  The American journal of cardiology 20031106

• Review of tadalafil in the treatment of erectile dysfunction.

  Expert opinion on pharmacotherapy 20031101

• A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.

  Clinical therapeutics 20031101

• Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.

  Clinical therapeutics 20031101

• The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.

  Journal of medicinal chemistry 20031009

• The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.

  Journal of medicinal chemistry 20031009

• Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.

  International journal of impotence research 20031001

• [Drug therapy of erectile dysfunction--the current status].

  Der Urologe. Ausg. A 20031001

• Cialis (tadalafil): a new treatment for erectile dysfunction.

  Hospital medicine (London, England : 1998) 20031001

• Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.

  Nature 20030904

• Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

  The Journal of urology 20030901

• Phosphodiesterase 5 inhibitors in male sexual dysfunction.

  Current opinion in urology 20030901

• [Medication of the month. Vardenafil (Levitra)].

  Revue medicale de Liege 20030901

• US advertising campaign begins for alternative to sildenafil.

  BMJ (Clinical research ed.) 20030830

• [Erectile dysfunction to be taken seriously. Otherwise, the psyche becomes limp, too].

  MMW Fortschritte der Medizin 20030807

• Hypogonadism and erectile dysfunction: the role for testosterone therapy.

  International journal of impotence research 20030801

• Coming attractions! New medications on the horizon for erectile dysfunction.

  Urologic nursing 20030801

• Effects of tadalafil on erectile dysfunction in men with diabetes.

  The Journal of urology 20030801

• Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

  Urology 20030701

• [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].

  Herz 20030601

• New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.

  The journal of the Royal Society for the Promotion of Health 20030601

• [Erectile dysfunction and phosphodiesterase type 5 inhibitors].

  Revue medicale de Bruxelles 20030601

• Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20030417

• Tadalafil: a new treatment for erectile dysfunction.

  BJU international 20030401

• The phosphodiesterase inhibitor 'war'.

  BJU international 20030401

• [How effective are PDE-5 inhibitors?].

  Der Urologe. Ausg. A 20030401

• [PDE-5 inhibitor with improved pharmacokinetics. Far-reaching return to normality].

  MMW Fortschritte der Medizin 20030313

• [Risk classification assures safety].

  MMW Fortschritte der Medizin 20030313

• Pharmacological management of erectile dysfunction.

  BJU international 20030301

• [Good sex inspite of erectile dysfunction. A new PDE-5 inhibitor gives more latitude].

  MMW Fortschritte der Medizin 20030220

• Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.

  Journal of medicinal chemistry 20030213

• Pharmacology of phosphodiesterase 5 inhibitors.

  The Canadian journal of urology 20030201

• Tadalafil: a new agent for erectile dysfunction.

  The Canadian journal of urology 20030201

• Tadalafil, a further innovation in the treatment of sexual dysfunction.

  Drugs of today (Barcelona, Spain : 1998) 20030201

• Tadalafil Lilly ICOS.

  Current opinion in investigational drugs (London, England : 2000) 20030101

• Tadalafil.

  Drugs 20030101

• Novel PDE5 inhibitors for the treatment of male erectile dysfunction.

  Reproductive biomedicine online 20030101

• [Efficacy and safety of the application of cialis for erectile dysfunction].

  Urologiia (Moscow, Russia : 1999) 20030101

• Effects of tadalafil on erectile dysfunction in men with diabetes.

  Diabetes care 20021201

• Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.

  International journal of impotence research 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction.

  Expert opinion on investigational drugs 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.

  European journal of medical research 20021029

• Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.

  The Journal of urology 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• [Erectile dysfunction].

  Actas urologicas espanolas 20021001

• Family complains that 'love drug''will smear their name.

  BMJ (Clinical research ed.) 20020907

• Phosphodiesterase 5 inhibitors: current status and potential applications.

  Nature reviews. Drug discovery 20020901

• Erectile dysfunction: oral pharmacotherapy options.

  International journal of clinical pharmacology and therapeutics 20020901

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020901

• [New medications for treatment of erectile dysfunction].

  Nihon rinsho. Japanese journal of clinical medicine 20020601

• Phosphodiesterase inhibition: erectile dysfunction is only part of the story.

  International journal of clinical practice 20020501

• Tadalafil (Cialis) for men with erectile dysfunction.

  International journal of clinical practice 20020501

• IC351 (tadalafil, Cialis): update on clinical experience.

  International journal of impotence research 20020201

• [Characteristics of patients hospitalized in a specialized hospital center after after attempted suicide].

  L'Encephale 20020101

• Pharmacology of phosphodiesterase-5 inhibitors.

  International journal of clinical practice 20020101

• PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.

  Annual review of sex research 20020101

• Towards optimal ED management: educational forum - II.

  The Canadian journal of urology 20011201

• Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells.

  Annals of the rheumatic diseases 20010701

• On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction.

  International journal of impotence research 20010201